RT Journal Article
T1 Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
A1 Salvador Martín, Sara
A1 Zapata Cobo, Paula
A1 Velasco, Marta
A1 Palomino Pérez, Laura María
A1 Clemente, Susana
A1 Segarra, Oscar
A1 Sánchez Sánchez, Cesar
A1 Tolín, Mar
A1 Moreno Álvarez, Ana
A1 Fernández Lorenzo, Ana
A1 Pérez Moneo, Begoña
A1 Loverdos, Inés
A1 Navas López, Victor Manuel
A1 Millán Jiménez, Antonio
A1 Magallares, Lorena
A1 Torres Peral, Ricardo
A1 García Romero, Ruth
A1 Pujol Muncunill, Gemma
A1 Merino Bohórquez, Vicente
A1 Rodríguez, Alejandro
A1 Salcedo, Enrique
A1 López Cauce, Beatriz
A1 Marín Jiménez, Ignacio
A1 Menchén Viso, Luis Alberto
A1 Laserna Mendieta, Emilio
A1 Lucendo Villarín, Alfredo J.
A1 Sanjurjo Sáez, María
A1 López Fernández, Luis A.
AB The genetic polymorphisms rs2395185 and rs2097432 in HLA genes have been associated with the response to anti-TNF treatment in inflammatory bowel disease (IBD). The aim was to analyze the association between these variants and the long-term response to anti-TNF drugs in pediatric IBD. We performed an observational, multicenter, ambispective study in which we selected 340 IBD patients under 18 years of age diagnosed with IBD and treated with anti-TNF drugs from a network of Spanish hospitals. Genotypes and failure of anti-TNF drugs were analyzed using Kaplan-Meier curves and Cox logistic regression. The homozygous G allele of rs2395185 and the C allele of rs2097432 were associated with impaired long-term response to anti-TNF drugs in children with IBD after 3 and 9 years of follow-up. Being a carrier of both polymorphisms increased the risk of anti-TNF failure. The SNP rs2395185 but not rs2097432 was associated with response to infliximab in adults with CD treated with infliximab but not in children after 3 or 9 years of follow-up. Conclusions: SNPs rs2395185 and rs2097432 were associated with a long-term response to anti-TNFs in IBD in Spanish children. Differences between adults and children were observed in patients diagnosed with CD and treated with infliximab.
PB MDPI
SN 1422-0067
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/72335
UL https://hdl.handle.net/20.500.14352/72335
LA eng
NO This research was funded by Instituto de Salud Carlos III, grant number PI19/00792 (L.A.L.-F.) and Juan Rodes program JR19/00005 (E.L.-M.), by Instituto de Investigación Sanitaria Gregorio Marañón, grant number 2021-II-postdoc-01 (S.S.-M.), and by Consejería de Educación, Universidades, Ciencia y Portavocía Comunidad de Madrid, grant number PEJ-2021-AI/BMD-21866 (P.Z.-C.). The study was co-funded by the European Union.
NO European Union
NO Consejería de Educación, Universidades, Ciencia y Portavocía Comunidad de Madrid
NO Instituto de Salud Carlos III
NO Juan Rodes program
NO Instituto de Investigación Sanitaria Gregorio Marañón
DS Docta Complutense
RD 6 may 2024